Trials / Completed
CompletedNCT04674813
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-95266 | Specified dose on specified days |
| DRUG | Fludarabine | Specified dose on specified days |
| DRUG | Cyclophosphamide | Specified dose on specified days |
| DRUG | Bendamustine | Specified dose on specified days |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2025-12-22
- Completion
- 2025-12-22
- First posted
- 2020-12-19
- Last updated
- 2026-02-09
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04674813. Inclusion in this directory is not an endorsement.